Literature DB >> 28467990

Current and Future Magnetic Resonance Technologies for Assessing Liver Disease in Clinical and Experimental Medicine.

Stephen J Bawden1, R A Scott, Guruprasad P Aithal.   

Abstract

BACKGROUND: In the past decades, a number of non-invasive methods have emerged for detecting and estimating liver fibrosis; these include both serum-based panels and imaging-based technology. Some of these methods are now being incorporated in clinical practice. However, the limitations of the current techniques include lack of organ specificity, sampling errors and limited ability to reflect the efficacy of interventions. Key Messages: Novel magnetic resonance (MR)-based techniques provide an opportunity to bring about further changes in the investigations and management of patients with liver diseases. Multimodal quantitative MR techniques enable the estimation of fat, iron accumulation, degree of liver injury/inflammation and fibrosis within the whole liver without the need for administering contrast agents. Architectural changes within the liver can be evaluated concurrently with portal haemodynamic changes allowing non-invasive assessment of portal hypertension and effects of interventions. A combination ultra-high field (7T) provides greater sensitivity with a potential to distinguish inflammation from fibrosis on imaging and determine specific types of fats (saturated vs. unsaturated) present within the liver using MR spectroscopy. 13C MR spectroscopy can estimate glutathione flux and rate of beta oxidation in-vivo providing novel tools for experimental studies that evaluate the efficacy of interventions as well as underlying mechanisms.
CONCLUSIONS: Translational research should focus on converting the potentials of these innovative methodologies into clinical applications for the benefit of patients.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Fibrosis; MRI; Magnetic resonance spectroscopy; Portal hypertension; Steatosis

Mesh:

Substances:

Year:  2017        PMID: 28467990     DOI: 10.1159/000456582

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  4 in total

Review 1.  Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges.

Authors:  Prarthana Thiagarajan; Guruprasad P Aithal
Journal:  J Clin Exp Hepatol       Date:  2019-03-13

Review 2.  Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy.

Authors:  Prarthana Thiagarajan; Stephen J Bawden; Guruprasad P Aithal
Journal:  J Clin Med       Date:  2021-02-07       Impact factor: 4.241

Review 3.  Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity.

Authors:  Partha Pal; Rajan Palui; Sayantan Ray
Journal:  World J Hepatol       Date:  2021-11-27

4.  Effects of sprint interval training on ectopic lipids and tissue-specific insulin sensitivity in men with non-alcoholic fatty liver disease.

Authors:  Jack A Sargeant; Stephen Bawden; Guruprasad P Aithal; Elizabeth J Simpson; Ian A Macdonald; Mark C Turner; Jessica Cegielski; Kenneth Smith; James L Dorling; Penny A Gowland; Myra A Nimmo; James A King
Journal:  Eur J Appl Physiol       Date:  2018-02-06       Impact factor: 3.078

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.